35 In this model, the effectiveness of ACEi in slowing the progression of normoalbuminuria to microalbuminuria was based on only one randomized trial of 156 normotensive, Enzalutamide mw middle-aged Israeli people.14 This trial showed that ACEi therapy was associated with an absolute risk reduction of 12.5% CI: 2–23% over 6 years. The effectiveness of ACEi is slowing the progression of microalbuminuria to diabetic kidney disease was also based on one study by.13 In 94 normotensive middle-aged Israeli people with type 2 diabetes, AER increased over 5 years from 123 to 310 mg/24 h
in the placebo group, and from 143 to 150 mg/24 h in the enalapril treatment group, showing a significant reduction in the rate of change of AER (P < 0.05). In the model by Golan et al.35 the transition time from macroalbuminuria to ESKD was
extrapolated from data on people with type 1 diabetes.36 Potential costs factored into the model included screening for microalbuminuria and proteinuria, drug costs and expenses incurred in treating ESKD with either dialysis or transplantation. The model also considered the effects of treatment non-compliance on cost-effectiveness and adjusted outcomes for quality of life changes. Compared with waiting until overt proteinuria develops, treating microalbuminuria with ACEi was estimated check details to reduce overt proteinuria from 16.8 to 10.4%, ESKD from 2.1 to 1.9% and total mortality from 15.2 to 14.7% over 10-years.35 By comparison, treating all people with type 2 diabetes with an ACEi, rather than screening for microalbuminuria, reduced microalbuminuria from 25.3 to 18.2%, overt proteinuria from 10.4 to 9.0%, ESKD from 1.4 to 1.2% and isometheptene total mortality from 14.7 to 14.6% over 10-years.35 ACEi treatment of overt proteinuria in normotensive,
people with type I diabetes reduces the progression to ESKD by about 40%.36 The rate of progression from gross proteinuria to ESKD is similar in people with type 1 and type 2 diabetes.37 However, it can not be assumed that ACEi will have the same effect on the prevention of ESKD in people with type 2 diabetes as shown for people with type 1 diabetes. This is because of a greater contribution of age-related intrarenal atherosclerosis and glomerulosclerosis leading to a decline in the number of functioning glomeruli. It is important to appreciate that cost-effectiveness is critically dependent on the life expectancy of the population it is applied to. Thus, treating microalbuminuria in elderly people will be less cost-effective than treating younger people. Cost-effectiveness is also reduced if more liberal criteria are used to diagnose diabetes or if screened people are unlikely to take prescribed medications.35 Cost-effectiveness also depends on the cost of ACEi. Projections based upon the current cost of ACEi may underestimate cost-effectiveness considering that many of these agents will soon be off patent and presumably substantially cheaper.